RESUMO
Cytomegalovirus (CMV) has a prominent position as the cause of severe cytomegalovirus infection (CMVI) in immunocompromised persons, such as: patients with primary or secondary immunodeficiency (risk group), blood/hemoproducts recipients, especially recipients of tissue and organ transplants, which have implications for difficult providing of CMV-seronegative (safe) blood. However, CMV-disease is manifested in the minority of immunocompetent persons. Sera of patients from the Center for Hemodialysis of the Clinic of Nephrology of the Military Medical Academy (MMA) were tested on the presence of CMVI markers. All patients belonged to the risk group considering the chronicity of the main disease, receiving of the large quantities of blood and as the possible potential recipients of kidney transplants. Testing was performed by commercial serologic-enzyme-immune tests (Abott--USA, Behring--Germany) for CMV antibodies of IgG and IgM classes by which was determined serologic state of patients. Test results: out of 106 tested sera samples, 100 (99.33%) were CMV-seropositive (CMV-IgG), 27 (25.47%) were positive on recent CMVI (CMV-IgM), 99 (93.39%) received the blood previously, the majority of patients were with the diagnosis of primary glomerulopathy--68 (64.15%) and tubulointerstitial nephropathy--32 (30.18). Such results indicate the potentional possibility of reactivation of latent CMV and development of CMVI, and in transplant recipients--its rejection. It can occur if appropriate measures of prevention from CMVI are not timely undertaken, which includes the providing of CMV-seronegative-safe blood/hemoproducts, as well as the appropriate application of combined medicamentous therapy by chemical agents and immunomodulators-specific hyperimmune anti-CMV immunoglobulins.
